Exact Mass: 429.1999
Exact Mass Matches: 429.1999
Found 96 metabolites which its exact mass value is equals to given mass value 429.1999
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
7-Benzylidenenaltrexone
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
Abiraterone sulfate
Abiraterone sulfate is a metabolite of abiraterone. Abiraterone is a drug used in castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) (prostate cancer not responding to androgen deprivation or treatment with antiandrogens). It is formulated as the prodrug abiraterone acetate and marketed under the trade name Zytiga. After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011. (Wikipedia)
7-Benzylidenenaltrexone
Hippuryl-histidyl-leucine
2-(2-(4-Phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid
8-Benzylcanadine
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.163 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.170
Ala Gly Pro Trp
Ala Gly Trp Pro
Ala Pro Gly Trp
Ala Pro Trp Gly
Ala Trp Gly Pro
Ala Trp Pro Gly
Gly Ala Pro Trp
Gly Ala Trp Pro
Gly Pro Ala Trp
Gly Pro Trp Ala
Gly Trp Ala Pro
Gly Trp Pro Ala
Pro Ala Gly Trp
Pro Ala Trp Gly
Pro Gly Ala Trp
Pro Gly Trp Ala
Pro Trp Ala Gly
Pro Trp Gly Ala
Trp Ala Gly Pro
Trp Ala Pro Gly
Trp Gly Ala Pro
Trp Gly Pro Ala
Trp Pro Ala Gly
Trp Pro Gly Ala
(S)-2-(9H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-3-(4-ISOPROPYL-PHENYL)-PROPIONIC ACID
4-[BUTYL([2-(1H-TETRAZOL-5-YL)[1,1-BIPHENYL]-4-YL]METHYL)AMINO]-5-PYRIMIDINECARBOXYLIC ACID
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-(3-methylphenyl)-N-(3-pyridinylmethyl)- (9CI)
3-{2-[4-(4-fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochlori de dihydrate
6-[2-Oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-(phenylmethyl)-7-triazolo[4,5-d]pyrimidinone
(6E)-6-benzylidene-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-7-(phenylmethylene)-, (5alpha)-
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
2-Amino-6-ethyl-4-(4-methoxyphenyl)-8-[(4-methoxyphenyl)methyl]-4,5-dihydropyrano[3,2-c]pyridine-3-carbonitrile
4-[[[2-(1-Azepanyl)ethyl-(2-furanylmethyl)amino]-sulfanylidenemethyl]amino]benzoic acid ethyl ester
2-[cyclohexyl-(2,4,6-trimethylphenyl)sulfonylamino]-N-(3-pyridinylmethyl)acetamide
1-methyl-4-[2-oxo-2-(N-(phenylmethyl)anilino)ethyl]-5-pyrrolo[3,2-b]pyrrolecarboxylic acid propan-2-yl ester
(4As,6Z,7aR,12bS)-6-benzylidene-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
(3S,12Z)-14,14,21,21-tetramethyl-22-oxa-5,11,16-triazahexacyclo[13.11.0.03,11.05,9.017,26.018,23]hexacosa-1(15),8,12,17(26),18(23),19,24-heptaene-4,10-dione
(3S,12Z)-14,14,21,21-tetramethyl-20-oxa-5,11,16-triazahexacyclo[13.11.0.03,11.05,9.017,26.019,24]hexacosa-1(15),8,12,17(26),18,22,24-heptaene-4,10-dione
[(8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulate
4F 4PP (oxalate)
4F 4PP (oxalate) is a selective 5-HT2A antagonist with almost as high affinity (Ki= 5.3 nM) as ketanserin but with a much lower affinity for 5-HT2C sites (Ki= 620 nM)[1][2][3][4].